GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

The Law Offices of Frank R. Cruz announces an investigation of GSK plc. ("GSK" or the "Company") (NYSE: GSK) on behalf of investors concerning the Company's possible violations of federal securities ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

GSK generated earnings per share of 23.2 pence last quarter, versus analysts’ average estimate of 20 pence. Last quarter, its ...

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...

Markets have hardly recovered from the DeepSeek shock and have just met trade tariff headwinds. Nonetheless, these stocks are ...

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.